New combo therapy targets Hard-to-Treat tumors
Disease control
Completed
This early-phase trial tested a new drug called RiMO-301, injected directly into tumors, along with standard radiation. It involved 32 people with advanced cancers that could not be cured. The main goal was to find a safe dose and check for any early signs of tumor shrinkage.
Phase: PHASE1 • Sponsor: Coordination Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 26, 2026 17:16 UTC